Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: OXA-181 producing E.coli ST410 in Switzerland

PROVIDER: PRJNA1163984 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR30785228_1.fastq.gz	Fastqsanger.gz
	SRR30785228_2.fastq.gz	Fastqsanger.gz
	SRR30785229_1.fastq.gz	Fastqsanger.gz
	SRR30785229_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 25

Similar Datasets

Project description:Complete Genome of oxa-48 producing E.coli, Switzerland

| PRJNA1187380 | ENA

Project description:Enterobacterales producing OXA-181, complete sequence

| PRJNA850540 | ENA

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

Project description:The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization mass spectrometry (A-MALDI) method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 KPC, 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/4; OXA-48 or OXA-181 or OXA-232; GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC & NDM; KPC & OXA; KPC & GES; NDM & OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase’s subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health.

2024-11-26 | PXD058284 | Pride

Klebsiella variicola strain:20KY165

Project description:An OXA-181-Producing Klebsiella variicola isolate in China

| PRJNA682525 | ENA

Enterobacterales

Project description:First Report of OXA-181 Producing Enterobacteriaceae, Lima-Peru

| PRJNA860216 | ENA

Escherichia coli strain:0808-167

Project description:Isolation of OXA-181 and OXA-232 carbapenemase-producing Escherichia coli and OXA-181 carbapenemase-producing Klebsiella pneumoniae from a pregnant woman returning from India to Japan

| PRJDB5948 | ENA

Project description:Escherichia coli clinical isolates ST410 co-producers of NDM-5 and OXA-181 and stability-derived strains.

| PRJNA577622 | ENA

Escherichia coli

Project description:Escherichia coli co-producing NDM-5 and OXA-181 carbapenemases, South Korea

| PRJNA421058 | ENA

Escherichia coli

Project description:ESBL-producing E.coli

| PRJNA657427 | ENA

Project description:Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020

| PRJNA872487 | ENA